TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7903962

Group type: EXPERIMENTAL
Intervention: c-erb B-2 overexpression
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: c-erb B-2 positivity
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: c-erb B-2 expression
Number of subjects: 107
Study: 2567896

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 12
Study: 21126827

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Personalized feedback only (FO)
Number of subjects: 198
Study: 89951

Group type: EXPERIMENTAL
Intervention: 10% nitrous oxide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All concentrations of nitrous oxide
Number of subjects: 9
Study: 31905885

Group type: EXPERIMENTAL
Intervention: Higher pasta consumption
Number of subjects: 2562

Group type: EXPERIMENTAL
Intervention: Pasta consumption
Number of subjects: 2562
Study: 28910328

Group type: EXPERIMENTAL
Intervention: CARE enhanced program
Number of subjects: 942

Group type: COMPARATOR
Intervention: Standard government nutrition and health package
Number of subjects: 942
Study: 26575248

Group type: EXPERIMENTAL
Intervention: Lavage with normal saline containing adrenaline [1:500,000], n = 30
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lavage with normal saline only, n = 30
Number of subjects: 60
Study: 23972865

Group type: EXPERIMENTAL
Intervention: Relaxation techniques and back massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 21146300

Group type: EXPERIMENTAL
Intervention: Active stimulation of the right M1 (10Hz, 80% motor threshold intensity, 1500 pulses per session)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Active stimulation of the right DLPFC (10Hz, 80% motor threshold intensity, 1500 pulses per session)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 36
Study: 20081798

Group type: EXPERIMENTAL
Intervention: Cavinton therapy
Number of subjects: 50
Study: 17574705

Group type: EXPERIMENTAL
Intervention: Soup preload (broth and vegetables served separately, chunky vegetable soup, chunky‐pureed vegetable soup, or pureed vegetable soup)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No preload (control group)
Number of subjects: 60
Study: 14760806

Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 215

Group type: COMPARATOR
Intervention: triamcinolone hexacetonide
Number of subjects: 215
Study: 11394463

Group type: EXPERIMENTAL
Intervention: Microbreaks at 20 min intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microbreaks at 40 min intervals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microbreaks at own discretion (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No breaks
Number of subjects: 0
Study: 9893736

Group type: EXPERIMENTAL
Intervention: Oral L-arginine (7 g twice daily)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8281847

Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg four times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg four times a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2525337

Group type: EXPERIMENTAL
Intervention: danazol, 800 mg/day (n = 10)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: danazol, 600 mg/day (n = 8)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: intranasal nafarelin acetate, 800 micrograms/day (n = 10)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: intranasal nafarelin acetate, 400 micrograms/day (n = 25)
Number of subjects: 53
Study: 31198103

Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 0
Study: 31357999

Group type: EXPERIMENTAL
Intervention: Quality incentive payments for general practices, including financial incentives for longer consultations, same day access, and timely follow-up after hospitalization.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Quality incentive payments for general practices
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care provided by control practices
Number of subjects: 36
Study: 27885472

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Plate-only open-door laminoplasty
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both ACDF and laminoplasty
Number of subjects: 34
Study: 25807927

Group type: EXPERIMENTAL
Intervention: Hydromorphone immediate-release (IR) tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydromorphone extended-release (ER) tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydromorphone IR and ER tablets (fed condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydromorphone-3-glucoside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydromorphone tablets (both IR and ER)
Number of subjects: 0
Study: 24048387

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day plus quetiapine 300 to 600 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Citalopram 40 mg/day plus placebo
Number of subjects: 41
Study: 21822077

Group type: COMPARATOR
Intervention: Midazolam (0.5 mg/kg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/kg) and Hydroxyzine (1 mg/kg)
Number of subjects: 84
Study: 19672787

Group type: EXPERIMENTAL
Intervention: Stable fat emulsion (Fabuless)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Milk fat in yoghurt (control)
Number of subjects: 15
Study: 17896496

Group type: COMPARATOR
Intervention: Group A: Parol and written notice about the content of root canal treatment
Number of subjects: 360

Group type: COMPARATOR
Intervention: Group B: Written notice and psychological communication
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Group C: Written notice, psychological communication, and local anesthesia
Number of subjects: 360
Study: 15472200

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment for 16 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (12 matched controls)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Untreated FCHL
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 12
Study: 11678837

Group type: COMPARATOR
Intervention: Four-track abdominal site (standard)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hip site
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Two-track abdomen site
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Two-track hip site
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All sites
Number of subjects: 96
Study: 9688432

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 18
Study: 7993812

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT) with involved marrow infusion
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not infused with involved marrow)
Number of subjects: 67
Study: 2917115

Group type: EXPERIMENTAL
Intervention: extradural 0.5% bupivacaine hydrochloride 0.75 mg kg‐1
Number of subjects: 144

Group type: COMPARATOR
Intervention: extradural 0.1% methadone hydrochloride 4 mg after bupivacaine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: continuous extradural infusion of methadone 0.3 mg h‐1 after operation
Number of subjects: 144
Study: 4584150

Group type: EXPERIMENTAL
Intervention: THC 3 μg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: THC 6 μg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: THC 9 μg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (0 μg/kg THC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: THC doses (3, 6, 9 μg/kg)
Number of subjects: 8
Study: 31967375

Group type: EXPERIMENTAL
Intervention: Blue-blocking (BB) glasses worn from 18:00 to 08:00 for seven consecutive nights
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (clear glasses) worn from 18:00 to 08:00 for seven consecutive nights
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blue-blocking (BB) glasses
Number of subjects: 20
Study: 30553120

Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers with guidance from women's group facilitators and community members
Number of subjects: 22
Study: 27813240

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 425

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 425
Study: 25874530

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both risperidone and olanzapine
Number of subjects: 166
Study: 23684901

Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention emphasizing reduced energy intake and portion-controlled menu suggestions
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 95
Study: 21078702

Group type: EXPERIMENTAL
Intervention: Combined exercise and general practitioner (GP) care group received 12 supervised exercise sessions at baseline and four booster sessions one year later.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard GP care (Control group)
Number of subjects: 120
Study: 19900653

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 5674
Study: 16772624

Group type: EXPERIMENTAL
Intervention: Fish oil (2 g/d)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 546
Study: 15009708

Group type: EXPERIMENTAL
Intervention: Ultraviolet-radiation (UVR) exposure at 1 minimal erythema dose (MED)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ultraviolet-radiation (UVR) exposure (0, 0.6, 1, or 2 MED)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ultraviolet-radiation (UVR) exposure
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dinitrochlorobenzene sensitization
Number of subjects: 22
Study: 11360127

Group type: EXPERIMENTAL
Intervention: ispaghula husk
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: guar gum
Number of subjects: 10
Study: 9243379

Group type: EXPERIMENTAL
Intervention: Ultrafast MP-RAGE sequence (TR = 5.8, TE = 2.9, TI = 20; imaging time, 15 seconds)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrafast three-dimensional gradient-echo sequence (TR = 8.2, TE = 3; imaging time, 18 seconds)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standard fast three-dimensional gradient-echo sequence (TR = 15, TE = 6; imaging time, 32 seconds)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 50
Study: 8374940

Group type: EXPERIMENTAL
Intervention: Gn-RH analogue (leuprolide)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3526790

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate 2 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine chloride 50 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 29935544

Group type: EXPERIMENTAL
Intervention: Baicalin 500 mg orally every day for 12 weeks
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 26638878

Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses
Number of subjects: 102

Group type: COMPARATOR
Intervention: Rocker‐sole footwear
Number of subjects: 102
Study: 25125229

Group type: EXPERIMENTAL
Intervention: Newcastle infant dialysis and ultrafiltration system (Nidus)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Peritoneal dialysis (PD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional haemodialysis (HD)
Number of subjects: 10
Study: 22322522

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction of gutta‐percha (LC)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Backfill ‐ Thermafil obturation technique (BT)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Thermafil technique (TT)
Number of subjects: 204
Study: 20869187

Group type: EXPERIMENTAL
Intervention: Usual care with structured counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17522841

Group type: EXPERIMENTAL
Intervention: Practical and mental training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Practical training
Number of subjects: 36
Study: 15758628

Group type: EXPERIMENTAL
Intervention: Right-side (R)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Combination (C)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Supine (S)
Number of subjects: 90
Study: 12227400

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD) patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CAPD patients
Number of subjects: 24
Study: 10525709

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 210

Group type: COMPARATOR
Intervention: Alfacalcidol 1 microgram/day
Number of subjects: 210
Study: 7600430

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: No vitamin E treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 22
Study: 1292438

Group type: EXPERIMENTAL
Intervention: Psychiatric treatment (PT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Multimodal behavioural therapy (MBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both PT and MBT
Number of subjects: 72
Study: 6442711

Group type: EXPERIMENTAL
Intervention: Auranofin 6 mg daily and placebo injection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sodium aurothiomalate 50 mg monthly and placebo tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both treatments (Auranofin and Sodium aurothiomalate)
Number of subjects: 24
Study: 30457162

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 134
Study: 29848769

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Unfractionated heparin or warfarin
Number of subjects: 10000
Study: 27695980

Group type: EXPERIMENTAL
Intervention: Mental fatigue plus caffeine ingestion (5 mg/kg) (MF-CAF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mental fatigue plus placebo (MF-PLA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mental fatigue (MF)
Number of subjects: 8
Study: 25894953

Group type: EXPERIMENTAL
Intervention: Adjunctive edivoxetine (12-18 mg/day)
Number of subjects: 1249

Group type: EXPERIMENTAL
Intervention: Adjunctive edivoxetine
Number of subjects: 1249

Group type: COMPARATOR
Intervention: Adjunctive placebo
Number of subjects: 1249
Study: 22941038

Group type: EXPERIMENTAL
Intervention: MGN-3
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 20298784

Group type: COMPARATOR
Intervention: 1.0 microg alfacalcidol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 0.5 microg eldecalcitol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 1.0 microg eldecalcitol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 0.5-1.0 microg eldecalcitol
Number of subjects: 59
Study: 18796622

Group type: EXPERIMENTAL
Intervention: Albumin-to-creatinine ratio (ACR)
Number of subjects: 3188

Group type: EXPERIMENTAL
Intervention: Quartiles of ACR
Number of subjects: 3188

Group type: EXPERIMENTAL
Intervention: ACR levels below microalbuminuria range
Number of subjects: 3188

Group type: COMPARATOR
Intervention: DPP intervention groups (placebo, lifestyle, metformin)
Number of subjects: 3188
Study: 16816561

Group type: EXPERIMENTAL
Intervention: Antibiotics (metronidazole plus erythromycin antenatally and metronidazole plus ampicillin intrapartum)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1510
Study: 12645827

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1,000 microg/day
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 10990474

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7711219

Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Fluorine Varnish
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control
Number of subjects: 362
Study: 2523645

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg or 5 mg twice daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 356497

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg) and Triamterene (50 mg) with possible addition of Methyldopa (up to 2 g daily)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and Triamterene
Number of subjects: 349
Study: 31848551

Group type: EXPERIMENTAL
Intervention: Soy protein (40 g daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Casein protein (40 g daily)
Number of subjects: 90
Study: 31288093

Group type: EXPERIMENTAL
Intervention: Traditional academic course with clinical ultrasound training (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ultrasound simulator training before clinical ultrasound training (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups received learning and training sessions on OUS after initial assessments
Number of subjects: 40
Study: 28711736

Group type: EXPERIMENTAL
Intervention: Low dose psilocybin (0.160 mg/kg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High dose psilocybin (0.215 mg/kg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Psilocybin (both doses)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 25876527

Group type: EXPERIMENTAL
Intervention: Continuous walking for 30 min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Accumulated walking (three 10 min bouts)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 25
Study: 23596237

Group type: EXPERIMENTAL
Intervention: Antituberculosis agents
Number of subjects: 90
Study: 21209030

Group type: EXPERIMENTAL
Intervention: Exercise + fortified milk
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study: 18310963

Group type: EXPERIMENTAL
Intervention: Interferon-beta (dose: 6 MU, daily for 4, 6, or 8 weeks)
Number of subjects: 111
Study: 16517183

Group type: EXPERIMENTAL
Intervention: MRI scanner noise (85 dB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: White noise (85 dB)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control condition (no noise)
Number of subjects: 24
Study: 14680546

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg/day (n = 7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg/day (n = 8)
Number of subjects: 15
Study: 11110233

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcipotriene 0.005% ointment twice daily
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tazarotene plus corticosteroid regimen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcipotriene group
Number of subjects: 120
Study: 8642525

Group type: EXPERIMENTAL
Intervention: 5% hypertonic saline solution
Number of subjects: 5

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 5
Study: 8366876

Group type: EXPERIMENTAL
Intervention: 100 mg saperconazole per day for 7 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 200 mg saperconazole per day for 7 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 100 mg saperconazole per day for 14 days
Number of subjects: 4
Study: 2889281

Group type: EXPERIMENTAL
Intervention: 6-month regimen of daily isoniazid plus rifampicin, supplemented by streptomycin twice a week for the first 6 months
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 9-month regimen of daily isoniazid plus rifampicin, supplemented by streptomycin twice a week for the first 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: 6-month regimen
Number of subjects: 51

Group type: COMPARATOR
Intervention: 9-month regimen
Number of subjects: 51
Study: 29793564

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate Partial Pulpotomy (PP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Formocresol Pulpotomy (FP)
Number of subjects: 25
Study: 27824741

Group type: EXPERIMENTAL
Intervention: 10% dextrose distention
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Sodium fluorescein
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Oral phenazopyridine
Number of subjects: 176

Group type: COMPARATOR
Intervention: Saline distention
Number of subjects: 176
Study: 24781851

Group type: EXPERIMENTAL
Intervention: Lifestyle change intervention
Number of subjects: 100
Study: 22525443

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) given at twice the recommended dietary allowance (RDA)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Six-multivitamin (MV) supplement given in one RDA as the 'standard of care'
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Six-multivitamin (MV) supplement
Number of subjects: 847
Study: 21243936

Group type: EXPERIMENTAL
Intervention: Sublingual peach immunotherapy (standardized peach extract quantified in mass units of Pru p 3) for 6 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 18506403

Group type: EXPERIMENTAL
Intervention: Surgically-assisted rapid maxillary expansion (SRME)
Number of subjects: 31
Study: 16457397

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 4895

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4895
Study: 12580687

Group type: EXPERIMENTAL
Intervention: Perceived infrequent parental monitoring
Number of subjects: 217